Bill SponsorBILLSPONSOR
Bill Sponsor
Politicians
Bills
House Bill 4215
115th Congress(2017-2018)
To amend title XVIII of the Social Security Act to ensure that providers of services receive adequate payments for the acquisition of hematopoietic stem cells under the Medicare program, and for other purposes.
Introduced
Introduced
Introduced in House on Nov 1, 2017
Overview
Text
Introduced in House 
Nov 1, 2017
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Introduced in House(Nov 1, 2017)
Nov 1, 2017
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Jump To
H. R. 4215 (Introduced-in-House)


115th CONGRESS
1st Session
H. R. 4215


To amend title XVIII of the Social Security Act to ensure that providers of services receive adequate payments for the acquisition of hematopoietic stem cells under the Medicare program, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

November 1, 2017

Mr. Paulsen (for himself, Mr. Kind, Ms. Matsui, and Mr. Bilirakis) introduced the following bill; which was referred to the Committee on Ways and Means

A BILL

To amend title XVIII of the Social Security Act to ensure that providers of services receive adequate payments for the acquisition of hematopoietic stem cells under the Medicare program, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Hematopoetic stem cell acquisition payments.

Section 1886(d)(5) of the Social Security Act (42 U.S.C. 1395ww(d)(5)) is amended by adding at the end the following new subparagraph:

“(M) (i) For cost reporting periods beginning on or after October 1, 2018, in the case of a provider of services that furnishes a hematopoetic stem cell transplant during such a period, the Secretary shall provide a separate payment for such provider consistent with the payment methodology for kidney acquisition costs under section 412.100 of title 42 of the Code of the Federal Register in lieu of taking into account such costs in any other payment made under this section. Such costs associated with such acquisition include costs associated with the following:

“(I) Tissue typing, including in the case that such typing is furnished by an independent laboratory.

“(II) Donor evaluation.

“(III) The collection of such cells.

“(IV) Furnishing the donor items or services relating to such collection.

“(V) Preservation and perfusion.

“(VI) Transportation of such cells.

“(VII) Using the services of the transplantation program described in section 379 of the Public Health Service Act.

“(VIII) Costs applicable to such collection that would otherwise be considered outpatient costs (including donor and recipient tissue typing and related services furnished prior to admission).

“(IX) Items or services related to such collection that are furnished by residents and interns not in approved teaching programs.

“(X) All pre-admission physicians’ services applicable to such collection.

“(XI) Other costs determined appropriated by the Secretary.

“(ii) In this subparagraph, the term ‘hematopoetic stem cell transplant’ means, with respect to an individual, the infusion of allogenic hematopoetic cells (including bone marrow, peripheral blood stem cells, and cord blood units, but not including embryonic stem cells) that are not more than minimally manipulated and are intended to reestablish hematopoetic function in such individual whose bone marrow or immune system is damaged or defective, or adversely affected by a congenital disorder.”.